Primary aldosteronism
Conditions
Interventions
Sponsors
National Hospital Organization
The Japan Endocrine Society
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Hypertensive patients in the outpatient clinics and hospitals, who full-fill the following 1) or 2) criteria: 1)treated hypertensive patients 2)untreated hypertensive patients with systolic blood pressure higher than 140mmHg or diastolic blood pressure higher than 90mmHg according to the guideline of the Japan Society of Hypertension
Exclusion criteria
Exclusion criteria: 1)pregnant patients 2)patients taking aldosterone antagonist within the last one month 3)patients taking beta blocker or diuretics if not feasible to change to Ca antagonist or alfa antagonist 3)patients with the following diseases: (1)secondary hypertension (renal hypertension,renovascular hypertension, primary aldosteronism, Cushing's syndrome, pheochromocytoma, etc) (2)patients whom the attending doctors decides not suitable for the entry because of the unstable stage of the following complications: coronary diseases, arrhythmia, severe valvular diseases, cerebrovascular diseases, acute and chronic renal failure (serum Cr higher than 3mg/dl), acute and chronic liver diseases 4) Patients whom the attending doctor decides not suitable for the entry of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1)Adherance of clinical guideline 2)Establishment of standard medication | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)Implementation rate of each diagnostic procedure 2)Successful rate of the localization 3) Comparison of the effects of treatments with aldosterone antagonist and those with conventional antihypertensive agents 4) Comparison of the effects of medical treatments and surgical treatment | — |
Countries
Japan
Contacts
Public ContactMitsuhide Naruse
National Hospital Organization, Kyoto Medical Center Department of Endocrinology, Clinical Research Institute for Endocrine and Metabolic Diseases
Outcome results
None listed